Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 641

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 641
---
 recorded within Equity and were also issued by TuHURA in lieu of paying equity issuance costs in connection with the consummation of the Reverse Recap, the assumption of the Penny Warrants being exercised would imply the issuance of additional Common Stock, thereby resulting in a reclassification of the Penny Warrants from Additionalpaid-incapital—Penny Warrants to Common Stock and Additionalpaid-incapital. As a result, the accounting for the Penny Warrants is determined to have zero net effect on total equity within the unaudited pro forma condensed combined balance sheet as of September 30, 2024 and only impacting the share capitalization of the Company by a nominal amount.Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized if the contracts continue to be classified in equity. TuHURA estimated the valuation of the Penny Warrants upon issuance based on a Black- Scholes simulation with key inputs and assumptions such as stock price, term, dividend yield, risk-free rate, and volatility; resulting in a fair value ascribed to the Penny Warrants of $1,642,867. As previously stated, however, the Penny Warrants were also issued as equity issuance costs by TuHURA to the investment bank in lieu of cash payment for fees that were directly attributable to the consummation of the Reverse Recap. As Legacy TuHURA was treated as the accounting acquirer for reporting purposes, these offering costs are treated as a reduction to Additionalpaid-incapital, however, management has preliminarily determined that the issuance of the underlying shares and increase to outstanding equity would effectively offset the reduction to Additionalpaid-incapital and the only current impacts are to common shares outstanding of TuHURA by 297,029.417
<div align='center'>**NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION**</div>

**The accounting treatment for the Penny Warrants issued and the value received for the consideration transferred is preliminary in nature and the final accounting treatment will be determined based on a number of factors, including additional analysis of the transaction and consideration of relevant accounting standards.

Kineta Exclusivity Agreement, July 2024 Private Placement

On July 8, 2024, Kineta and Legacy TuHURA entered into the Exclusivity Agreement for the potential acquisition of Kineta’s KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset.

KVA